Skip to main content

Day: March 27, 2025

EDF:Press release on the filing of the 2024 Universal Registration Document and Annual Financial Report

Press release on the filing of the 2024 Universal Registration Document and Annual Financial Report EDF’s Universal Registration Document for the 2024 financial year was filed today with the French financial markets’ authority (Autorité des marchés financiers). In particular, the following documents are included in the Universal Registration Document:the 2024 Annual Financial Report; the report of the Board of Directors, including the report on corporate governance, the vigilance plan and information on sustainability; the statutory auditors’ reports and details of their fees; the certification report on sustainability information.The Universal Registration Document is available on EDF website at the following address and is available in compliance with the regulation: https://www.edf.fr/en/the-edf-group/dedicated-sections/investors/regulated-information About...

Continue reading

Orange: Publication of the 2024 Universal Registration Document

Press releaseParis, 27 March 2025 Publication of the 2024 Universal Registration Document On 27 March 2025, Orange filed its 2024 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in France in ESEF format. The document includes the following information:the 2024 Annual Financial Report; the Report of the Board of Directors on Corporate Governance; the Sustainability Statement; information on the next Combined Ordinary and Extraordinary Shareholders’ Meeting of 21 May 2025.The Registration Document is available to the public on Orange’s corporate website: https://www.orange.com/en/regulated-information.     About OrangeOrange is one of the world’s leading telecommunications operators with revenues of 40.3 billion euros in 2024 and 127,000 employees worldwide at 31 December 2024, including 71,000 employees...

Continue reading

Resolutions from Zealand Pharma’s Annual General Meeting 2025

Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma’s Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today held its Annual General Meeting of 2025 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved. Proposals adopted at the Annual General Meeting: Annual Report The Annual General Meeting acknowledged the management’s report on Zealand Pharma’s activities in the past financial year and Zealand Pharma’s audited Annual Report for 2024 was approved. The Annual General Meeting...

Continue reading

VivoPower Agrees to Grant Exclusivity to Energi Subject to Increase in Non-Binding All-Cash Takeover Offer to Enterprise Value of US$180 Million

LONDON, March 27, 2025 (GLOBE NEWSWIRE) — VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”) has agreed to grant Energi Holdings Limited (“Energi”) an exclusivity period of 8 weeks to conduct due diligence subject to Energi increasing its non-binding all-cash takeover proposal to acquire the non-affiliated shareholders of VivoPower at an enterprise valuation of US$180 million. This represents an increase from US$120 million. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The unsolicited takeover proposal is an all-cash offer for all non-affiliated free float shares of VivoPower at a revised enterprise value of US$180 million...

Continue reading

BUREAU VERITAS – Filing of the 2024 Universal Registration Document

PRESS RELEASE Paris – March 27, 2025 Filing of the 2024 Universal Registration Document On March 27, 2025, Bureau Veritas filed its 2024 Universal Registration Document (“Document d’enregistrement universel 2024”) with the French stock exchange regulatory authority, the Autorité des marchés financiers (AMF). The Universal Registration Document was filed in xHTML format and has been made available to the public free of charge in accordance with the regulations in force. It includes notably:The 2024 annual financial report, comprising Bureau Veritas SA statutory financial statements and Group consolidated financial statements; The Board of Directors’ report on corporate governance; The Statutory Auditors’ reports, The information related to the fees paid to Statutory Auditors for the financial year 2024; The information related...

Continue reading

Fluxys Belgium – Regulated information: 2024 annual results

Overview of 2024 annual results     Consolidated net profit was EUR 82.1 million (EUR 77.4 million in 2023)  Proposed allocation of profit submitted to the Annual General Meeting on 13 May 2025: gross dividend of EUR 1.40 per share (2024: EUR 1.40 per share)  Belgium remains essential hub for energy supplies in NW Europe  Switch to high-calorific gas successfully completed Green Logix: first biomethane plant directly connected to the Fluxys network Fluxys hydrogen appointed operator of hydrogen transmission network in Belgium Partner in the hydrogen link with Luxembourg, France and Germany Working with industry to cut CO2 in Belgium North Sea Integration Model: working together towards net zero emissions Good results towards our ESG targets 91 new colleagues hired   Key financial...

Continue reading

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

2024 Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050  ̶  Further data on 24-month follow-up for all patients of the Phase I part expected in Q2 2025Randomization in Phase II part of the Phase I/II trial evaluating TG4050 in head and neck cancer patients due to be completed in Q4 2025New trial with individualized cancer vaccine planned to start in Q4 2025 in a second indicationBusiness funded until the end of April 2026Conference call scheduled today at 6 p.m. CET (in English). See details below.   Strasbourg, France, March 27, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial...

Continue reading

Cegedim Full year 2024 results: Operating profitability improved

 PRESS RELEASEQuarterly financial information as of December 31, 2024IFRS – Regulated information – Audited Full year 2024 results: Cegedim’s operating profitability improved2024 revenues rose 6.3% to €654.5 million Recurring operating income(1) increased 24.7% to €39.5 million Recurring operating margin came to 6.0% in 2024, up from 5.1% in 2023Boulogne-Billancourt, France, March 27, 2025, after the market close Cegedim generated consolidated revenues of €654.5 million in 2024, an increase of 6.3%, and recurring operating income(1) of €39.5 million, a 24.7% increase. Recurring operating margin was 6.0%, up from 5.1% one year earlier. Consolidated income statement  2024 2023 Change  (in €m) (in %) (in €m) (in %) (in %)Revenue 654.5 100% 616.0 100.0% +6.3%EBITDA(1) 123.6 18.9% 108.8 17.7% +13.5%Depreciation...

Continue reading

Intchains Group Limited’s Goldshell launches its innovative product today: Goldshell Byte enables dual mining with swappable cards

SINGAPORE, March 27, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG), a leading innovator in integrated solutions consisting of efficient mining products for altcoins, is proud to announce its launch of the Goldshell Byte under its Goldshell brand on 27 March 2025. Goldshell Byte is an innovative home miner with a standard dual-slot mining base and hot-swappable mining hash boards, enabling miners to simultaneously apply two different algorithms and easily switch mining cards based on market conditions. Currently, Goldshell has released two companion cards for the Byte product: the AE Card and DG Card. The default hash rate of the AE Card is 4.5 MH/s ±5%, while the DG Card operates at 65 MH/s ±5%. Mr Ding Qiang, CEO of ICG, said: “The Goldshell Byte enables quick switching mining algorithms without replacing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.